摘 " "要 " "目的 " "探討左房應(yīng)變參數(shù)聯(lián)合左心耳開口處排空速度(LAAeV)預(yù)測持續(xù)性心房顫動(dòng)(PeAF)消融術(shù)后早期復(fù)發(fā)的臨床價(jià)值。方法 " "前瞻性選取于我院行導(dǎo)管消融術(shù)的PeAF患者122例,依據(jù)3個(gè)月隨訪結(jié)果分為復(fù)發(fā)組和未復(fù)發(fā)組。消融當(dāng)日應(yīng)用常規(guī)超聲心動(dòng)圖獲取左室舒張末期內(nèi)徑(LVEDD)、左房前后徑(LAD)、左房容積指數(shù)(LAVI)、左房射血分?jǐn)?shù)(LAEF)、左室射血分?jǐn)?shù)(LVEF);脈沖多普勒獲取二尖瓣口舒張?jiān)缙诜逯盗魉伲‥),組織多普勒獲取室間隔及左室側(cè)壁二尖瓣環(huán)舒張?jiān)缙谶\(yùn)動(dòng)速度平均值(e’),計(jì)算E/e’;經(jīng)食管超聲心動(dòng)圖獲取LAAeV;二維斑點(diǎn)追蹤技術(shù)獲取左室整體縱向應(yīng)變(LVGLS)、左房儲(chǔ)器期應(yīng)變(LASr)、左房管道期應(yīng)變(LAScd)、左房泵期應(yīng)變(LASct),比較兩組上述參數(shù)的差異。采用二元Logistic回歸分析篩選預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的獨(dú)立影響因素;繪制受試者工作特征(ROC)曲線分析各獨(dú)立影響因素單獨(dú)及聯(lián)合應(yīng)用預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的診斷效能。結(jié)果 " "最終納入74例PeAF患者,其中復(fù)發(fā)組26例,未復(fù)發(fā)組48例。兩組LAD、LAVI、LAAeV、LVGLS、LASr、LASct比較差異均有統(tǒng)計(jì)學(xué)意義(均Plt;0.05),LVEDD、LAEF、LVEF、E/e’及LAScd比較差異均無統(tǒng)計(jì)學(xué)意義。二元Logistic回歸分析顯示,LAAeV、LASr、LASct均為預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的獨(dú)立危險(xiǎn)因素(OR=1.789、2.290、1.204,均Plt;0.05),由此建立回歸方程為:Logit(P)=-13.587+0.548×LASr+0.846×LASct+0.296×LAAeV。ROC曲線分析顯示,LAAeV、LASr、LASct預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的曲線下面積分別為0.839、0.821、0.709,三者聯(lián)合應(yīng)用的曲線下面積為0.938,高于各參數(shù)單獨(dú)應(yīng)用,差異均有統(tǒng)計(jì)學(xué)意義(均Plt;0.001)。結(jié)論 " "左房應(yīng)變參數(shù)聯(lián)合LAAeV在預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)中具有一定的臨床應(yīng)用價(jià)值。
關(guān)鍵詞 " "超聲心動(dòng)描記術(shù);斑點(diǎn)追蹤技術(shù),二維;左房功能;左心耳排空速度;心房顫動(dòng);導(dǎo)管消融術(shù)
[中圖法分類號]R540.45 " " [文獻(xiàn)標(biāo)識碼]A
Clinical value of left atrial strain parameters combined with left atrial appendage emptying velocity in predicting early recurrence after
persistent atrial fibrillation ablation
SHI Weiqiang1,LU Jing1,LI Na’na1,YAN Aidi2,REN Yongfeng1
1.Department of Ultrasound Medicine,2.Department of Cardiovascular Medicine,Bozhou Hospital Affiliated to
Anhui Medical University,Bozhou 236800,China
ABSTRACT " "Objective " "To investigate the clinical value of left atrial strain parameters combined with left atrial appendage emptying velocity(LAAeV) in predicting early recurrence after persistent atrial fibrillation(PeAF) ablation.Methods " "A total of 122 PeAF patients undergoing catheter ablation in our hospital were prospectively enrolled,according to the results of a 3-month follow-up,they were divided into recurrence group and non-recurrence group.On the day of ablation,conventional echocardiography was used to obtain the left ventricular end-diastolic diameter(LVEDD),left atrial anteroposterior diameter(LAD),left atrial volume index(LAVI),left atrial ejection fraction(LAEF),and left ventricular ejection fraction(LVEF).Pulse Doppler was used to obtain the early diastolic peak velocity of mitral inflow(E),tissue Doppler was used to obtain the early diastolic mitral annular velocity(e’) at the septal and lateral walls,followed by calculation of E/e’.Transesophageal echocardiography(TEE) was used to obtain the LAAeV.Two-dimensional speckle tracking echocardiography(2D-STE) was used to obtain left ventricular global longitudinal strain(LVGLS),left atrial reservoir strain (LASr),left atrial conduit strain (LAScd),and left atrial pump strain (LASct).The differences of above parameters between the two groups were compared.Binary Logistic regression analysis was performed to identify independent predictors for predicting early recurrence after PeAF ablation.Receiver operating characteristic(ROC) curve was drawn to analyze the diagnostic performance of individual and combined parameters in predicting early recurrence after PeAF ablation.Results " "Totally 74 PeAF patients were selected,including 26 cases in the recurrence group and 48 cases in the non-recurrence group.Significant differences were observed between the two groups in LAD,LAVI,LAAeV,LVGLS,LASr,and LASct(all Plt;0.05),while no significant differences were found in LVEDD,LAEF,LVEF,E/e’,and LAScd.Binary Logistic regression analysis identified that LAAeV,LASr,and LASct were independent risk factors for predicting early recurrence after PeAF ablation(OR=1.789,2.290,1.204,all Plt;0.05),and the regression equation was established as:Logit(P)=-13.587+0.548×LASr+0.846×LASct+0.296×LAAeV.ROC curve analysis showed that the area under the curve(AUC) of LAAeV,LASr,and LASct in predicting early recurrence after PeAF ablation were 0.839,0.821,and 0.709,respectively.The combined AUC of the three parameters was 0.938,which was higher than that of each parameter alone (all Plt;0.001).Conclusion " "Left atrial strain parameters combined with LAAeV have a certain clinical value in predicting early recurrence after PeAF ablation.
KEY WORDS " "Echocardiography;Speckle tracking imaging,two-dimensional;Left atrial function;Left atrial appendage emptying velocity;Atrial fibrillation;Catheter ablation
心房顫動(dòng)(atrial fibrillation,AF)作為臨床常見的心律失常類型,其發(fā)生率隨著人口老齡化進(jìn)程加劇呈顯著上升趨勢,嚴(yán)重影響患者的生活質(zhì)量,同時(shí)也大大增加了社會(huì)負(fù)擔(dān),已成為一個(gè)緊迫的公共衛(wèi)生問題[1-2]。持續(xù)性心房顫動(dòng)(persistent atrial fibrillation,PeAF)是指AF發(fā)作持續(xù)超過7 d,且需要通過心臟復(fù)律(藥物或電復(fù)律)才能恢復(fù)竇性心律的一種心律失常[3]。PeAF因無法自發(fā)轉(zhuǎn)復(fù)竇性心律,持續(xù)的血流動(dòng)力學(xué)紊亂會(huì)導(dǎo)致心房內(nèi)血液瘀滯,進(jìn)而誘發(fā)心房纖維化重構(gòu),因此其危害較陣發(fā)性AF更大,患者死亡率也大大增加。研究[4]顯示導(dǎo)管消融術(shù)是治療PeAF的主要手段,但PeAF消融術(shù)后3個(gè)月內(nèi)有高達(dá)50%的患者可能出現(xiàn)房性心律失常,這一現(xiàn)象被稱為早期復(fù)發(fā)[5-6],明確早期復(fù)發(fā)的危險(xiǎn)因素對于臨床決策和患者預(yù)后具有重要意義。既往研究[7-10]顯示左房應(yīng)變參數(shù)和左心耳開口處排空速度(LAAeV)與PeAF消融術(shù)后早期復(fù)發(fā)密切相關(guān)?;诖?,本研究旨在探討左房應(yīng)變參數(shù)聯(lián)合LAAeV在預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)中的價(jià)值,為臨床個(gè)性化治療提供參考依據(jù)。
資料與方法
一、研究對象
前瞻性選取2022年10月至2024年2月我院診斷為PeAF的患者122 例,男55例,女67例,年齡51~80歲,平均(64.04±6.15)歲,體質(zhì)量指數(shù)(BMI)17~33 kg/m2,平均(25.66±2.76)kg/m2。納入標(biāo)準(zhǔn):①符合PeAF診斷標(biāo)準(zhǔn)[3];②首次進(jìn)行導(dǎo)管消融術(shù);③術(shù)后隨訪3個(gè)月;④能配合完成相關(guān)檢查,且資料完整。排除標(biāo)準(zhǔn):①左房內(nèi)有血栓;②先天性心臟病、瓣膜病、心功能不全;③既往有心臟手術(shù)史。本研究經(jīng)我院醫(yī)學(xué)倫理委員會(huì)批準(zhǔn)(批準(zhǔn)號:亳醫(yī)倫理第252號),所有患者均簽署知情同意書。
二、儀器與方法
1.儀器:使用Philips iE33彩色多普勒超聲診斷儀,經(jīng)胸超聲心動(dòng)圖(transthoracic echocardiography,TTE)檢查使用X5-1探頭,頻率1~5 MHz;經(jīng)食管超聲心動(dòng)圖(transesophageal echocardiography,TEE)檢查使用X7-2T探頭,頻率3~8 MHz;配備QLAB定量分析軟件。
2.超聲心動(dòng)圖檢查:行消融術(shù)當(dāng)日患者于平靜狀態(tài)下取左側(cè)臥位,同步連接心電圖,先行TTE檢查,調(diào)節(jié)掃查深度、角度、增益使左心內(nèi)膜清晰顯示,保持幀頻60~100幀/s,記錄胸骨旁左室長軸及心尖四腔心、三腔心、兩腔心切面連續(xù)4個(gè)心動(dòng)周期動(dòng)態(tài)圖像并存儲(chǔ),測量左房前后徑(LAD)、 左室舒張末期內(nèi)徑(LVEDD);采用雙平面Simpson法獲取左房收縮末期容積,以體表面積標(biāo)化計(jì)算左房容積指數(shù)(LAVI),以及左房射血分?jǐn)?shù)(LAEF)、左室射血分?jǐn)?shù)(LVEF);脈沖多普勒獲取二尖瓣口舒張?jiān)缙诜逯盗魉伲‥),組織多普勒獲取室間隔及左室側(cè)壁二尖瓣環(huán)舒張?jiān)缙谶\(yùn)動(dòng)速度平均值(e’),計(jì)算E/e’。TEE檢查時(shí)探頭于0~180°切面調(diào)節(jié)取樣角度以獲取LAAeV。然后應(yīng)用二維斑點(diǎn)追蹤技術(shù)(two-dimensional speckle tracking imaging,2D-STI)于心尖四腔心、三腔心、兩腔心切面獲取動(dòng)態(tài)圖像,啟動(dòng)QLAB定量分析軟件,選擇Auto Strain LV和Auto Strain LA功能,自動(dòng)測量左室整體縱向應(yīng)變(LVGLS)、左房儲(chǔ)器期應(yīng)變(LASr)、左房管道期應(yīng)變(LAScd)、左房泵期應(yīng)變(LASct),所有應(yīng)變參數(shù)均取絕對值進(jìn)行統(tǒng)計(jì)分析。以上檢查均由3名具有10年以上超聲心動(dòng)圖檢查經(jīng)驗(yàn)的醫(yī)師完成,所有參數(shù)均重復(fù)測量2次,如差值較大則進(jìn)行第3次測量,取2次較為接近的平均值進(jìn)行統(tǒng)計(jì)分析。
3.一般資料獲?。翰殚啿v收集患者性別、年齡、BMI、病程、合并癥(如高血壓、糖尿病、冠心病、腦卒中等)、藥物使用情況(如抗心律失常藥物、抗凝藥物等),以及N末端B型鈉尿肽前體(NT-ProBNP)水平。
4.隨訪:術(shù)后3個(gè)月通過門診復(fù)查心電圖、超聲心動(dòng)圖及電話進(jìn)行回訪,對可疑復(fù)發(fā)而心電圖檢查結(jié)果陰性患者采用動(dòng)態(tài)心電圖進(jìn)一步明確。PeAF復(fù)發(fā)診斷標(biāo)準(zhǔn)[4]:術(shù)后3個(gè)月出現(xiàn)癥狀性房性心律失?;蛐碾妶D/動(dòng)態(tài)心電圖記錄到≥30 s的任何房性快速性心律失常。
三、統(tǒng)計(jì)學(xué)處理
應(yīng)用SPSS 22.0統(tǒng)計(jì)軟件,采用Shapiro-Wilk法結(jié)合P-P圖進(jìn)行正態(tài)性檢驗(yàn),符合正態(tài)分布的計(jì)量資料以x±s表示,采用t檢驗(yàn);不符合正態(tài)分布的計(jì)量資料以M(Q1,Q3)表示,采用Mann-Whitney U檢驗(yàn)。計(jì)數(shù)資料以頻數(shù)或率表示,采用χ2檢驗(yàn)。采用二元Logistic回歸分析篩選預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的獨(dú)立影響因素;繪制受試者工作特征(ROC)曲線分析各獨(dú)立影響因素單獨(dú)及聯(lián)合應(yīng)用預(yù)測PeAF術(shù)后早期復(fù)發(fā)的診斷效能,曲線下面積(AUC)比較采用Delong檢驗(yàn)。Plt;0.05為差異有統(tǒng)計(jì)學(xué)意義。
結(jié) "果
一、隨訪結(jié)果及分組
排除資料不全、檢查期間不能維持竇性心律、圖像采集不滿意、隨訪丟失等患者后,本研究最終納入74例患者,根據(jù)復(fù)發(fā)情況分為復(fù)發(fā)組26例和未復(fù)發(fā)組48例。
二、兩組一般資料比較
復(fù)發(fā)組與未復(fù)發(fā)組NT-proBNP比較差異有統(tǒng)計(jì)學(xué)意義(Plt;0.05);其余一般資料比較差異均無統(tǒng)計(jì)學(xué)意義。見表1。
三、兩組超聲心動(dòng)圖檢查結(jié)果比較
復(fù)發(fā)組與未復(fù)發(fā)組LAD、LAVI、LAAeV、LVGLS、LASr、LASct比較差異均有統(tǒng)計(jì)學(xué)意義(均Plt;0.05);LVEDD、LVEF、LAEF、E/e’及LAScd比較差異均無統(tǒng)計(jì)學(xué)意義。見表2和圖1,2。
四、二元Logistic回歸分析
單因素Logistic回歸分析顯示,NT-proBNP、LAVI、LASr、LASct、LVGLS、LAAeV均為預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的影響因素(均Plt;0.05);多因素Logistic回歸分析顯示,LASr、LAsct、LAAeV均為預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的獨(dú)立危險(xiǎn)因素(OR=1.789、2.290、1.204,均Plt;0.05)。見表3。由此建立回歸方程為:Logit(P)=-13.587+0.548×LASr+0.846×LASct+0.296×LAAeV。
五、ROC曲線分析
ROC曲線分析顯示,LAAeV、LASr、LASct預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的AUC分別為0.839(95%可信區(qū)間:0.747~0.930)、0.821(95%可信區(qū)間:0.722~0.919)、0.709(95%可信區(qū)間:0.588~0.830),靈敏度分別為70.8%、85.4%、70.8%,特異度分別為84.6%、61.5%、94.1%;三者聯(lián)合應(yīng)用的AUC為0.938(95%可信區(qū)間:0.920~1.000),靈敏度為89.6%,特異度為92.3%,聯(lián)合應(yīng)用的AUC高于各參數(shù)單獨(dú)應(yīng)用,差異均有統(tǒng)計(jì)學(xué)意義(均Plt;0.001)。見表4和圖3。
討 "論
PeAF與患者死亡、卒中和外周動(dòng)脈栓塞的發(fā)生風(fēng)險(xiǎn)相關(guān)。導(dǎo)管消融是目前公認(rèn)的最佳治療手段,但由于消融術(shù)后復(fù)發(fā)率較高,近年已引起國內(nèi)學(xué)者的廣泛關(guān)注[7,11]。2D-STI測得的左房應(yīng)變參數(shù)是目前評估左房重構(gòu)的可靠參數(shù)之一,而左房重構(gòu)已被證實(shí)與AF患者治療及預(yù)后密切相關(guān)[12]。2D-STI具有無角度依賴性、可重復(fù)性好等優(yōu)點(diǎn),可通過追蹤左房運(yùn)動(dòng)軌跡獲取左房應(yīng)變參數(shù),但該方法對圖像質(zhì)量要求較高,而AF患者心室率控制不如人意,因此在臨床工作中采集高質(zhì)量的超聲心動(dòng)圖圖像具有一定難度。研究[13]發(fā)現(xiàn)AF患者發(fā)作期與發(fā)作間期其左房應(yīng)變參數(shù)相差較大,LAAeV不僅是反映左心耳功能的常用參數(shù),還可以反映左房功能[14]。本研究在嚴(yán)格控制竇性心律的情況下采集PeAF患者超聲心動(dòng)圖圖像,聯(lián)合左房應(yīng)變參數(shù)和LAAeV構(gòu)建預(yù)測模型,旨在探討其預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的臨床價(jià)值,為臨床制定個(gè)性化治療方案提供參考依據(jù)。
研究[15]顯示,NT-proBNP和左室充盈壓力升高可作為預(yù)測AF患者左心耳功能障礙和血栓的可靠替代標(biāo)志物。本研究結(jié)果顯示,復(fù)發(fā)組NT-proBNP較非復(fù)發(fā)組升高,差異有統(tǒng)計(jì)學(xué)意義(Plt;0.05);單因素Logistic回歸分析也顯示NT-proBNP為PeAF消融術(shù)后早期復(fù)發(fā)的影響因素。分析原因?yàn)椋篘T-proBNP是由腦鈉肽分解產(chǎn)生,而腦鈉肽是由于心肌細(xì)胞牽拉擴(kuò)張刺激而產(chǎn)生,由于長期血液瘀滯和心房功能下降使PeAF患者心房顯著擴(kuò)大,心房肌細(xì)胞釋放大量腦鈉肽,因此NT-proBNP在一定程度上可以反映左房功能[16]。LAD不僅被認(rèn)為是反映左房重構(gòu)的良好參數(shù),其也是評估PeAF預(yù)后的參數(shù)之一,研究[17]發(fā)現(xiàn)LAD增加與PeAF消融術(shù)后復(fù)發(fā)相關(guān),但其并非反映左房擴(kuò)張程度的最佳參數(shù),原因可能為左房是一個(gè)立體結(jié)構(gòu)且擴(kuò)張也并非呈對稱性。本研究中復(fù)發(fā)組LAD大于未復(fù)發(fā)組,差異有統(tǒng)計(jì)學(xué)意義(Plt;0.05);但二元Logistic回歸分析顯示其并非預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的影響因素。與上述研究結(jié)論一致。左房體積能夠更好地反映左房擴(kuò)張程度,因此本研究檢測參數(shù)中納入了LAVI,結(jié)果發(fā)現(xiàn)復(fù)發(fā)組LAVI較非復(fù)發(fā)組增大,差異有統(tǒng)計(jì)學(xué)意義(Plt;0.05);單因素Logistic回歸分析顯示LVAI為預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的影響因素(Plt;0.05),表明LAVI可以反映左房纖維化重構(gòu)程度,而左房重構(gòu)又與PeAF預(yù)后密切相關(guān),與Kranert等[18]研究結(jié)果一致。雖然本研究多因素Logistic回歸分析顯示NT-proBNP和LAVI并非預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的獨(dú)立危險(xiǎn)因素,但在臨床工作中對于這些參數(shù)較高的PeAF患者也應(yīng)增加術(shù)后隨訪次數(shù),盡量降低其術(shù)后早期復(fù)發(fā)的發(fā)生風(fēng)險(xiǎn)。
研究[19]發(fā)現(xiàn),2D-STI參數(shù)可準(zhǔn)確評估左房儲(chǔ)備、管道及泵功能,較左房容積變化參數(shù)能夠更敏感地評估左房功能受損。陳蘭花等[7]研究發(fā)現(xiàn)LASr為預(yù)測陣發(fā)性AF患者消融術(shù)后復(fù)發(fā)的可靠參數(shù),Bierg等[8]研究也發(fā)現(xiàn)LASr和LASct均為預(yù)測PeAF消融術(shù)后復(fù)發(fā)的獨(dú)立危險(xiǎn)因素,且在左房大小正常(LAVIlt;34 ml/m2)的患者中,僅LASct為預(yù)測PeAF消融術(shù)后復(fù)發(fā)的獨(dú)立預(yù)測因素。本研究結(jié)果顯示,復(fù)發(fā)組與未復(fù)發(fā)組LASr、LASct、LVGLS比較差異均有統(tǒng)計(jì)學(xué)意義(均Plt;0.05),其中LASr和LASct均為預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的獨(dú)立危險(xiǎn)因素(OR=1.789、2.290,均Plt;0.05),這可能是因?yàn)镻eAF主要損害左房泵功能和儲(chǔ)存功能,患者左房功能越差提示其左房結(jié)構(gòu)重構(gòu)和電生理重構(gòu)程度越嚴(yán)重,即使通過消融術(shù)恢復(fù)了竇性心律,由于電生理傳導(dǎo)紊亂的存在,患者仍可能出現(xiàn)房性心律失常。此外,無論何種類型的AF,在發(fā)作期間所測得的數(shù)值均不可靠。因此,本研究采用藥物使患者短暫恢復(fù)竇性心律后再進(jìn)行檢查,由于患者的具體情況不同,所使用的藥物劑量也有所差異(藥物劑量可能會(huì)短暫影響患者左房功能),從而導(dǎo)致研究結(jié)果存在一定偏差。今后研究需進(jìn)一步細(xì)化藥物劑量對檢測結(jié)果的影響。
既往研究[8]發(fā)現(xiàn)LAAeVgt;38 cm/s為預(yù)測PeAF患者消融術(shù)后維持竇性心律結(jié)局的截?cái)嘀?,Ma等[9]也認(rèn)為術(shù)前TEE測得的LAAeV可作為PeAF消融術(shù)后復(fù)發(fā)的預(yù)測參數(shù)。本研究結(jié)果顯示,復(fù)發(fā)組與未復(fù)發(fā)組LAAeV比較差異有統(tǒng)計(jì)學(xué)意義(Plt;0.05),且其為PeAF消融術(shù)后早期復(fù)發(fā)的獨(dú)立危險(xiǎn)因素(OR=1.204,Plt;0.001),原因可能為左心耳是左房的一個(gè)重要緩沖壓力結(jié)構(gòu),在左房功能受損導(dǎo)致其內(nèi)壓力升高時(shí),左心耳能夠及早發(fā)現(xiàn)并做出相應(yīng)改變,尤其在PeAF患者中表現(xiàn)更為顯著。但LAAeV也存在一定局限,其除了受左房功能及測量角度影響外,還受自身因素影響,如左心耳大小、形狀、內(nèi)部梳狀肌及肌小梁數(shù)量等,因此本研究通過聯(lián)合左房應(yīng)變參數(shù)進(jìn)行分析以減少單一因素的不足。ROC曲線分析顯示,LASr、LASct聯(lián)合LAAeV預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)的AUC為0.938,高于各參數(shù)單獨(dú)應(yīng)用,差異均有統(tǒng)計(jì)學(xué)意義(均Plt;0.001),表明多參數(shù)聯(lián)合應(yīng)用能夠提高PeAF消融術(shù)后早期復(fù)發(fā)的預(yù)測價(jià)值。
綜上所述,左房應(yīng)變參數(shù)聯(lián)合LAAeV在預(yù)測PeAF消融術(shù)后早期復(fù)發(fā)中具有一定的應(yīng)用價(jià)值,可為臨床評估預(yù)后及制定個(gè)體化治療方案提供參考依據(jù)。但本研究樣本量小,且為單中心研究,在病史采集過程中患者主觀性較強(qiáng)或并未發(fā)現(xiàn)心律失常,今后應(yīng)擴(kuò)大樣本量進(jìn)行多中心研究進(jìn)一步探討PeAF消融術(shù)后復(fù)發(fā)的可能影響因素。
參考文獻(xiàn)
[1] Zhang J,Johnsen SP,Guo Y,et al.Epidemiology of atrial fibrillation:geographic/ecological risk factors,age,sex,genetics[J].Card Electrophysiol Clin,2021,13(1):1-23.
[2] Burdett P,Lip GYH.Atrial fibrillation in the United Kingdom:predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs[J].Eur Heart J,2022,8(2):187-194.
[3] Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Eur J Cardiothorac Surg,2016,50(5):e1-e88.
[4] Hindricks G,Potpara T,Dagres N,et al.Corrigendum to:2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J].Eur Heart J,2021,42(40):4194.
[5] Hodges G,Bang CN,Torp-Pedersen C,et al.Significance of early recurrence of atrial fibrillation after catheter ablation:a nationwide Danish cohort study[J].J Interv Card Electrophysiol,2021,60(2):271-278.
[6] Kaixuan F,Xuefeng Z,Hongxia C,et al.Re-recognize early recurrence of persistent atrial fibrillation[J].Front Cardiovasc Med,2023,30(5):101145695.
[7] 陳蘭花,李慧忠,陳榕,等.左心房應(yīng)變聯(lián)合RT-3DE對老年人陣發(fā)性AF消融術(shù)后復(fù)發(fā)的預(yù)測[J].中國超聲醫(yī)學(xué)雜志,2023,39(10):1121-1125.
[8] Bjerg AN,Grundtvig KS,Kasper D,et al.Left atrial contractile strain predicts recurrence of atrial tachyarrhythmia after catheter ablation[J].Int J Cardiol,2022,6(1):51-57.
[9] Ma XX,Zhang YL,Hu B,et al.Association between left atrial appendage emptying velocity,N-terminal plasma brain natriuretic peptide levels,and recurrence of atrial fibrillation after catheter ablation[J].J Interv Card Electrophysiol,2017,48(3):343-350.
[10] Hotamgari SR,Sheth AR,Ahmad J,et al.Low left atrial appendage emptying velocity is a predictor of atrial fibrillation recurrence after catheter ablation[J].J Cardiovasc Electrophysiol,2022,33(8):1705-1711.
[11] 郝曉一,張穎,劉真真,等.左心耳收縮期峰值應(yīng)變率預(yù)測陣發(fā)性房顫導(dǎo)管消融術(shù)后復(fù)發(fā)[J].中國超聲醫(yī)學(xué)雜志,2024,40(1):36-39.
[12] 彭夏鋒,李庫林,王如興.二維斑點(diǎn)追蹤對房顫所致的左房重構(gòu)及房顫相關(guān)疾病發(fā)生的評估[J].江蘇大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2019,29(5):451-455.
[13] Bajaj M,Smith R,Baghdadi S,et al.Association of left atrial appendage emptying velocity with type of atrial fibrillation[J].Circulation,2023,148(Suppl 1):A17844.
[14] Kiliszek M,Uzi?b?o-?yczkowska B,Krzy?anowski K,et al.Value of left atrial strain in predicting recurrence after atrial fibrillation ablation[J].J Clin Med,2023,12(12):4034.
[15] Yu GI,Cho KI,Kim HS,et al.Association between the N-terminal plasma brain natriuretic peptide levels or elevated left ventricular filling pressure and thromboembolic risk in patients with non-valvular atrial fibrillation[J].J Cardiol,2016,68(2):110-116.
[16] 王慶亞,林佳,張宇禎,等.多指標(biāo)聯(lián)合評估模型對陣發(fā)性心房顫動(dòng)導(dǎo)管射頻消融術(shù)后復(fù)發(fā)的預(yù)測價(jià)值[J].臨床心血管病雜志,2021,37(1):62-68.
[17] Njoku A,Kannabhiran M,Arora R,et al.Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation:a Meta-analysis[J].Europace,2018,20(1):33-42.
[18] Kranert M,Shchetynska-Marinova T,Liebe V,et al.Recurrence of atrial fibrillation in dependence of left atrial volume index[J].In Vivo,2020,34(2):889-896.
[19] Sonaglioni A,Vincenti A,Baravelli M,et al.Prognostic value of global left atrial peak strain in patients with acute ischemic stroke and no evidence of atrial fibrillation[J].Int J Cardiovasc Imaging,2018,35(4):603-613.
(收稿日期:2024-08-08)